

51. (Amended once) A method for [altering] inhibiting [the] a humoral immune response in an animal comprising administering a pharmaceutical composition which comprises a therapeutically effective amount of a soluble lymphotoxin- $\beta$  receptor.

61. (Amended once) A method for [altering] inhibiting [the] a humoral immune response in an animal comprising administering a pharmaceutical composition which comprises a therapeutically effective amount of an antibody directed against LT- $\beta$  receptor.

65. (Amended once) A method for [altering] inhibiting [the] a humoral immune response in an animal comprising administering a pharmaceutical composition which comprises a therapeutically effective amount of an antibody directed against surface LT ligand.

84. (Amended once) A method for [altering] disrupting the association of immune complexes and B cell follicles in a patient comprising administering an amount of a soluble lymphotoxin- $\beta$  receptor to said patient.

91. (Amended once) A method for [altering] disrupting the association of immune complexes and B cell follicles in a patient comprising administering an amount of an antibody directed against LT- $\beta$  receptor to said patient.

94. (Amended once) A method for [altering] disrupting the association of immune complexes and B cell follicles in a patient comprising administering an amount of an antibody directed against surface LT ligand.

### **Remarks**

#### Amendments

In accordance with section 1.121 a copy of the pending claims and a clean copy of the "amended" specification paragraphs are provided in Appendix A.

#### *In the Title*

The title has been amended as requested to more distinctly describe the invention.